XYF-19 is under clinical development by Xi’An Yufan Biotechnology and currently in Phase I for Chronic Lymphocytic Leukemia (CLL). According to GlobalData, Phase I drugs for Chronic Lymphocytic Leukemia (CLL) have a 69% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how XYF-19’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
XYF-19 overview
XYF-19 is under development for the treatment of relapsed/refractory B cell hematological malignancies including B cell acute lymphoblastic leukemia (B-ALL), chronic lymphocytic leukemia (CLL), follicular lymphoma, marginal zone B-cell lymphoma, Waldenstrom macroglobulinemia, hairy cell leukemia, diffuse large B-Cell lymphoma, Burkitt lymphoma and mantle cell lymphoma. It is administered through intravenous route. The therapeutic candidate comprises of autologous T-cells genetically transduced with a lentiviral vector to express chimeric antigen receptors (CAR) targeting cells expressing CD19. The CAR-T cells are electroporated with CRISPR guide RNA to disrupt expression of endogenous HPK1.
For a complete picture of XYF-19’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
